The addition of angiotensin receptor blockers to angiotens-inconverting enzyme inhibitors—What has time told us?
The neurohormonal hypothesis for the pathogenesis of heart failure found an early champion in the angiotensinconverting enzyme (ACE) inhibitors. More recently, the β-blockers and aldosterone receptor antagonists have provided significant support by demonstrating marked additive clinical benefit. Within this context, angiotensin receptor blockers (ARBs) were specifically designed to antagonize one of the most potent contributors to the development and progression of heart failure, angiotensin. This review discusses the recent evidence for the addition of ARBs to standard therapy with ACE inhibitors and suggests how this evidence may be used to care for patients.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 21.Nakao N, Yoshimura A, Morita H, et al.: Combination treatment of angiotensin-II receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003, 361:117–124. This small, single-center study of 366 patients demonstrated that combination therapy with trandolapril and losartan significantly decreased time to worsening of renal function and improved survival, compared with therapy with either agent alone.PubMedCrossRefGoogle Scholar
- 22.McKelvie RS, Yusuf S, Pericak D, et al.: Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100:1056–1064. This important exploratory pilot study assesses the effect of candesartan, enalapril, and their combination on multiple endpoints, including neurohormonal changes and ventricular remodeling. Combination therapy reduced neurohormones and limited progressive increase in ventricular volumes in patients with heart failure.PubMedGoogle Scholar
- 23.Cohn JN, Tognoni G: A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667–1675. The Val-HeFT trial demonstrated that the addition of valsartan to a standard heart failure regimen, including ACE inhibitors, improved morbidity and mortality, primarily through reduced heart failure hospitalizations. Subgroup analysis also demonstrated dramatic benefits of valsartan compared with placebo in ACE inhibitor-intolerant patients.PubMedCrossRefGoogle Scholar
- 24.McMurray JJ, Ostergren J, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003, 362:767–771. The CHARM-Added trial is part of the CHARM program, and it addressed the question of the utility of adding candesartan to a standard heart failure regimen, including ACE inhibitors and β-blockers. Candesartan significantly reduced the combined endpoint of cardiovascular death and heart failure hospitalizations and decreased cardiovascular death, compared with placebo.PubMedCrossRefGoogle Scholar
- 25.Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893–1906. The VALIANT trial enrolled patients after MI with evidence of heart failure and randomized them to valsartan, captopril, or the combination. The study demonstrated the noninferiority of valsartan to captopril with respect to mortality, but the combination had no additional benefit.PubMedCrossRefGoogle Scholar
- 26.Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709–717. The Randomized Aldactone Evaluation Study enrolled patients with symptomatic heart failure and demonstrated that the addition of spironolactone, an aldosterone antagonist, to a regimen with ACE inhibitors improved survival.PubMedCrossRefGoogle Scholar
- 27.Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309–1321. The Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study enrolled patients after MI with evidence of heart failure and randomized them to therapy with eplerenone, a selective aldosterone antagonist, or placebo. Patients treated with eplerenone had decreased all-cause mortality and less frequent hospitalizations.PubMedCrossRefGoogle Scholar
- 31.Pitt B, Poole-Wilson PA, Segal R, et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355:1582–1587. ELITE II was the first mortality trial using an ARB in patients with heart failure. The study demonstrated a nonsignificant increase in mortality in the losartan-treated patients, compared with placebo. Although some suggest that the losartan was significantly underdosed, the study clearly refutes any suggestion of a survival benefit for losartan.PubMedCrossRefGoogle Scholar